In clinical settings, anti-cancer immunity has been mostly assessed by hematoxylin and eosin (H&E) evaluation of tumor infiltrating lymphocytes (TILs) and immunohistochemical (IHC) evaluation of programmed death ligand 1 (PD-L1). Here, CD274 is linked to neoplasm.